Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.
Table 1
Individual Disclosures for the NCCN Pancreatic Adenocarcinoma Panel
ArnoldLD, PatelAV, YanY, et al.Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?Cancer Epidemiol Biomarkers Prev2009;18:2397–2405.
ArnoldLD, PatelAV, YanY, Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?Cancer Epidemiol Biomarkers Prev 2009;18:2397–2405.10.1158/1055-9965.EPI-09-008019723915)| false
SimardEP, WardEM, SiegelR, Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118–128.10.3322/caac.2014122281605)| false
EhemanC, HenleySJ, Ballard-BarbashR, et al.Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer2012;118:2338–2366.
EhemanC, HenleySJ, Ballard-BarbashR, Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338–2366.2246073310.1002/cncr.27514)| false
SmithBD, SmithGL, HurriaA, et al.Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol2009;27:2758–2765.
SmithBD, SmithGL, HurriaA, Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–2765.10.1200/JCO.2008.20.898319403886)| false
WorniM, GullerU, WhiteRR, et al.Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas2013;42:1157–1163.
WorniM, GullerU, WhiteRR, Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 2013;42:1157–1163.10.1097/MPA.0b013e318291fbc523867367)| false
VisserBC, MaY, ZakY, et al.Failure to comply with NCCN Guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford)2012;14:539–547.
VisserBC, MaY, ZakY, Failure to comply with NCCN Guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford) 2012;14:539–547.10.1111/j.1477-2574.2012.00496.x)| false
HoosWA, JamesPM, RahibL, Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol 2013;31:3432–3438.2396018510.1200/JCO.2013.49.4823)| false
AndersonMA, ZolotarevskyE, CooperKL, et al.Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol2012;107:1730–1739.
AndersonMA, ZolotarevskyE, CooperKL, Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol 2012;107:1730–1739.10.1038/ajg.2012.288)| false
BosettiC, LucenteforteE, SilvermanDT, et al.Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol2012;23:1880–1888.
BosettiC, LucenteforteE, SilvermanDT, Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012;23:1880–1888.10.1093/annonc/mdr541)| false
LynchSM, VrielingA, LubinJH, et al.Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol2009;170:403–413.
LynchSM, VrielingA, LubinJH, Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009;170:403–413.1956106410.1093/aje/kwp134)| false
VrielingA, Bueno-de-MesquitaHB, BoshuizenHC, et al.Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer2010;126:2394–2403.
VrielingA, Bueno-de-MesquitaHB, BoshuizenHC, Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;126:2394–2403.19790196)| false
AntwiSO, EckertEC, SabaqueCV, et al.Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control2015;26:1583–1591.
AntwiSO, EckertEC, SabaqueCV, Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control 2015;26:1583–1591.10.1007/s10552-015-0652-y26293241)| false
AlsamarraiA, DasSL, WindsorJA, PetrovMS.Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol2014;12:1635–1644.
AlsamarraiA, DasSL, WindsorJA, PetrovMS.Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2014;12:1635–1644.10.1016/j.cgh.2014.01.03824509242)| false
LucenteforteE, La VecchiaC, SilvermanD, et al.Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol2012;23:374–382.
LucenteforteE, La VecchiaC, SilvermanD, Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012;23:374–382.10.1093/annonc/mdr120)| false
BagnardiV, RotaM, BotteriE, et al.Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer2015;112:580–593.
BagnardiV, RotaM, BotteriE, Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer 2015;112:580–593.10.1038/bjc.2014.57925422909)| false
MaisonneuveP, AmarS, LowenfelsAB.Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol 2017;28:985–995.10.1093/annonc/mdx01928453689)| false
LarssonSC, OrsiniN, WolkA.Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007;120:1993–1998.10.1002/ijc.2253517266034)| false
LiD, MorrisJS, LiuJ, Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009;301:2553–2562.10.1001/jama.2009.88619549972)| false
PatelAV, RodriguezC, BernsteinL, et al.Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev2005;14:459–466.
PatelAV, RodriguezC, BernsteinL, Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:459–466.10.1158/1055-9965.EPI-04-0583)| false
GenkingerJM, KitaharaCM, BernsteinL, et al.Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol2015;26:2257–2266.
GenkingerJM, KitaharaCM, BernsteinL, Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol 2015;26:2257–2266.10.1093/annonc/mdv355)| false
BehrensG, JochemC, SchmidD, et al.Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis. Eur J Epidemiol2015;30:279–298.
BehrensG, JochemC, SchmidD, Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis. Eur J Epidemiol 2015;30:279–298.2577375210.1007/s10654-015-0014-9)| false
LarssonSC, WolkA.Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012;106:603–607.2224079010.1038/bjc.2011.585)| false
ThiébautAC, JiaoL, SilvermanDT, et al.Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst2009;101:1001–1011.
ThiébautAC, JiaoL, SilvermanDT, Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst 2009;101:1001–1011.10.1093/jnci/djp16819561318)| false
GenkingerJM, WangM, LiR, Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Ann Oncol 2014;25:1106–1115.2463194310.1093/annonc/mdu019)| false
RohrmannS, LinseisenJ, NöthlingsU, et al.Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer2013;132:617–624.
RohrmannS, LinseisenJ, NöthlingsU, Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2013;132:617–624.2261075310.1002/ijc.27637)| false
WolpinBM, NgK, BaoY, Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012;21:82–91.10.1158/1055-9965.EPI-11-083622086883)| false
WaterhouseM, RischHA, BosettiC, et al.Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Ann Oncol2015;26:1776–1783.
WaterhouseM, RischHA, BosettiC, Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Ann Oncol 2015;26:1776–1783.10.1093/annonc/mdv236)| false
DuellEJ, LucenteforteE, OlsonSH, et al.Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol2012;23:2964–2970.
DuellEJ, LucenteforteE, OlsonSH, Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012;23:2964–2970.10.1093/annonc/mds140)| false
LowenfelsAB, MaisonneuveP, CavalliniG, Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433–1437.10.1056/NEJM1993052032820018479461)| false
BracciPM, WangF, HassanMM, Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 2009;20:1723–1731.10.1007/s10552-009-9424-x19760029)| false
MajumderS, BockornyB, BakerWL, et al.Association between HBsAg positivity and pancreatic cancer: a meta-analysis. J Gastrointest Cancer2014;45:347–352.
MajumderS, BockornyB, BakerWL, Association between HBsAg positivity and pancreatic cancer: a meta-analysis. J Gastrointest Cancer 2014;45:347–352.10.1007/s12029-014-9618-724788082)| false
SeoMS, YeoJ, HwangIC, Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis. Clin Rheumatol 2019;38:3109–3116.3127069710.1007/s10067-019-04660-9)| false
ChariST, LeibsonCL, RabeKG, Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504–511.1608370710.1016/j.gastro.2005.05.007)| false
LiaoWC, TuYK, WuMS, et al.Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ2015;350:g7371.
GulloL, PezzilliR, Morselli-LabateAM.; Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331:81–84.10.1056/NEJM1994071433102038208269)| false
RaghavanSR, BallehaninnaUK, ChamberlainRS.The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review. Pancreas2013;42:1210–1217.
RaghavanSR, BallehaninnaUK, ChamberlainRS.The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review. Pancreas 2013;42:1210–1217.10.1097/MPA.0b013e3182a6db8e24152946)| false
RosaJA, Van LindaBM, AbourizkNN.New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J Clin Gastroenterol1989;11:211–215.
RosaJA, Van LindaBM, AbourizkNN.New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J Clin Gastroenterol 1989;11:211–215.10.1097/00004836-198904000-000202661661)| false
ElenaJW, SteplowskiE, YuK, et al.Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control2013;24:13–25.
ElenaJW, SteplowskiE, YuK, Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 2013;24:13–25.10.1007/s10552-012-0078-823112111)| false
SongS, WangB, ZhangX, et al.Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. PLoS One2015;10:e0134321.
SongS, WangB, ZhangX, Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. PLoS One 2015;10:e0134321.10.1371/journal.pone.013432126222906)| false
BodmerM, BeckerC, MeierC, et al.Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol2012;107:620–626.
BodmerM, BeckerC, MeierC, Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620–626.2229040210.1038/ajg.2011.483)| false
SinghS, SinghPP, SinghAG, et al.Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol2013;108:510–519., quiz 520.
SinghS, SinghPP, SinghAG, Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:510–519., quiz 520.2339955610.1038/ajg.2013.7)| false
FranciosiM, LucisanoG, LapiceE, Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.2393652010.1371/journal.pone.0071583)| false
SorannaD, ScottiL, ZambonA, et al.Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist2012;17:813–822.
SorannaD, ScottiL, ZambonA, Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012;17:813–822.2264353610.1634/theoncologist.2011-0462)| false
WangZ, LaiST, XieL, et al.Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract2014;106:19–26.
WangZ, LaiST, XieL, Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014;106:19–26.2483714410.1016/j.diabres.2014.04.007)| false
ChaiteerakijR, PetersenGM, BamletWR, et al.Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol2016;34:1898–1904.
ChaiteerakijR, PetersenGM, BamletWR, Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol 2016;34:1898–1904.10.1200/JCO.2015.63.351127069086)| false
SadeghiN, AbbruzzeseJL, YeungSC, et al.Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res2012;18:2905–2912.
SadeghiN, AbbruzzeseJL, YeungSC, Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905–2912.2246583110.1158/1078-0432.CCR-11-2994)| false
ToriolaAT, Stolzenberg-SolomonR, DalidowitzL, et al.Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer2014;111:181–185.
ToriolaAT, Stolzenberg-SolomonR, DalidowitzL, Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer 2014;111:181–185.10.1038/bjc.2014.22424786605)| false
HumphrisJL, JohnsAL, SimpsonSH, Clinical and pathologic features of familial pancreatic cancer. Cancer 2014;120:3669–3675.10.1002/cncr.2886325313458)| false
WangW, ChenS, BruneKA, PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007;25:1417–1422.10.1200/JCO.2006.09.245217416862)| false
CattsZA, BaigMK, MilewskiB, et al.Statewide retrospective review of familial pancreatic cancer in Delaware, and frequency of genetic mutations in pancreatic cancer kindreds. Ann Surg Oncol2016;23:1729–1735.
CattsZA, BaigMK, MilewskiB, Statewide retrospective review of familial pancreatic cancer in Delaware, and frequency of genetic mutations in pancreatic cancer kindreds. Ann Surg Oncol 2016;23:1729–1735.10.1245/s10434-015-5026-x26727920)| false
KleinAP, BruneKA, PetersenGM, Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634–2638.10.1158/0008-5472.CAN-03-382315059921)| false
BruneKA, LauB, PalmisanoE, Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010;102:119–126.2006819510.1093/jnci/djp466)| false
RainoneM, SinghI, Salo-MullenEE, et al.An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. JAMA Oncol2020;6:764–771.
RainoneM, SinghI, Salo-MullenEE, An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. JAMA Oncol 2020;6:764–771.10.1001/jamaoncol.2019.596332053139)| false
JenneDE, ReimannH, NezuJ, Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38–43.10.1038/ng0198-38)| false
KorsseSE, HarinckF, van LierMG, et al.Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet2013;50:59–64.
KorsseSE, HarinckF, van LierMG, Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 2013;50:59–64.10.1136/jmedgenet-2012-10127723240097)| false
GiardielloFM, BrensingerJD, TersmetteAC, Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–1453.1111306510.1053/gast.2000.20228)| false
van LierMG, WagnerA, Mathus-VliegenEM, et al.High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:1258–1264., author reply 1265.
van LierMG, WagnerA, Mathus-VliegenEM, High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010;105:1258–1264., author reply 1265.10.1038/ajg.2009.72520051941)| false
SuGH, HrubanRH, BansalRK, et al.Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol1999;154:1835–1840.
SuGH, HrubanRH, BansalRK, Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835–1840.10.1016/S0002-9440(10)65440-510362809)| false
HowesN, LerchMM, GreenhalfW, et al.Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol2004;2:252–261.
HowesN, LerchMM, GreenhalfW, Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004;2:252–261.10.1016/S1542-3565(04)00013-815017610)| false
LowenfelsAB, MaisonneuveP, DiMagnoEP, Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997;89:442–446.10.1093/jnci/89.6.4429091646)| false
WhelanAJ, BartschD, GoodfellowPJ.Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med1995;333:975–977.
WhelanAJ, BartschD, GoodfellowPJ.Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975–977.10.1056/NEJM1995101233315057666917)| false
de SnooFA, BishopDT, BergmanW, et al.Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res2008;14:7151–7157.
de SnooFA, BishopDT, BergmanW, Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008;14:7151–7157.1898101510.1158/1078-0432.CCR-08-0403)| false
VasenHF, GruisNA, FrantsRR, et al.Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer2000;87:809–811.
VasenHF, GruisNA, FrantsRR, Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809–811.10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U)| false
AaltonenLA, SalovaaraR, KristoP, et al.Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med1998;338:1481–1487.
AaltonenLA, SalovaaraR, KristoP, Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.10.1056/NEJM1998052133821019593786)| false
LindorNM, PetersenGM, SpurdleAB, Pancreatic cancer and a novel MSH2 germline alteration. Pancreas 2011;40:1138–1140.10.1097/MPA.0b013e318220c217)| false
HampelH, FrankelWL, MartinE, Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851–1860.1587220010.1056/NEJMoa043146)| false
HampelH, FrankelWL, MartinE, Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783–5788.1880960610.1200/JCO.2008.17.5950)| false
KastrinosF, MukherjeeB, TayobN, Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302:1790–1795.1986167110.1001/jama.2009.1529)| false
WinAK, YoungJP, LindorNM, et al.Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol2012;30:958–964.
WinAK, YoungJP, LindorNM, Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30:958–964.2233194410.1200/JCO.2011.39.5590)| false
HuC, HartSN, BamletWR, et al.Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev2016;25:207–211.
HuC, HartSN, BamletWR, Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev 2016;25:207–211.10.1158/1055-9965.EPI-15-045526483394)| false
IqbalJ, RagoneA, LubinskiJ, The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012;107:2005–2009.2309980610.1038/bjc.2012.483)| false
van AsperenCJ, BrohetRM, Meijers-HeijboerEJ, et al.Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet2005;42:711–719.
van AsperenCJ, BrohetRM, Meijers-HeijboerEJ, Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42:711–719.10.1136/jmg.2004.02882916141007)| false
ZhenDB, RabeKG, GallingerS, BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 2015;17:569–577.2535697210.1038/gim.2014.153)| false
LiedeA, KarlanBY, NarodSA.Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol2004;22:735–742.
LiedeA, KarlanBY, NarodSA.Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735–742.10.1200/JCO.2004.05.055)| false
HolterS, BorgidaA, DoddA, et al.Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol2015;33:3124–3129.
HolterS, BorgidaA, DoddA, Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 2015;33:3124–3129.10.1200/JCO.2014.59.7401)| false
LucasAL, FradoLE, HwangC, et al.BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer2014;120:1960–1967.
LucasAL, FradoLE, HwangC, BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer 2014;120:1960–1967.2473734710.1002/cncr.28662)| false
Salo-MullenEE, O’ReillyEM, KelsenDP, Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121:4382–4388.2644092910.1002/cncr.29664)| false
SlaterEP, LangerP, NiemczykE, PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010;78:490–494.10.1111/j.1399-0004.2010.01425.x20412113)| false
RobertsNJ, JiaoY, YuJ, ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012;2:41–46.2258516710.1158/2159-8290.CD-11-0194)| false
SyngalS, BrandRE, ChurchJM, et al.ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol2015;110:223–262., quiz 263.
TanakaM, Fernández-del CastilloC, AdsayV, et al.International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology2012;12:183–197.
TanakaM, Fernández-del CastilloC, AdsayV, International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183–197.10.1016/j.pan.2012.04.00422687371)| false
TanakaM, Fernández-Del CastilloC, KamisawaT, et al.Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology2017;17:738–753.
TanakaM, Fernández-Del CastilloC, KamisawaT, Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738–753.2873580610.1016/j.pan.2017.07.007)| false
Del ChiaroM, VerbekeC, SalviaR, European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013;45:703–711.10.1016/j.dld.2013.01.01023415799)| false
YchouM, ConroyT, SeitzJF, et al.An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol2003;14:481–489.
YchouM, ConroyT, SeitzJF, An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14:481–489.1259835710.1093/annonc/mdg119)| false
ConroyT, PaillotB, FrançoisE, et al.Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol2005;23:1228–1236.
ConroyT, PaillotB, FrançoisE, Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228–1236.1571832010.1200/JCO.2005.06.050)| false
YchouM, DesseigneF, GuimbaudR, et al.Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment of metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]. J Clin Oncol2007;25 (June 20 Suppl):4516.
ConroyT, DesseigneF, YchouM, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–1825.2156134710.1056/NEJMoa1011923)| false
PeixotoRD, HoM, RenoufDJ, et al.Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol2015.
PeixotoRD, HoM, RenoufDJ, Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol 2015.)| false
SukerM, BeumerBR, SadotE, et al.FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol2016;17:801–810.
Gourgou-BourgadeS, Bascoul-MolleviC, DesseigneF, et al.Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol2013;31:23–29.
Gourgou-BourgadeS, Bascoul-MolleviC, DesseigneF, Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31:23–29.10.1200/JCO.2012.44.486923213101)| false
LoweryMA, YuKH, AdelNG, et al. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. ASCO Meeting Abstracts 2012;30:4057.
LoweryMA, YuKH, AdelNG, Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. ASCO Meeting Abstracts 2012;30:4057.10.1200/jco.2012.30.15_suppl.4057)| false
SteinSM, JamesES, DengY, et al.Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer2016;114:737–743.
SteinSM, JamesES, DengY, Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016;114:737–743.10.1038/bjc.2016.4527022826)| false
BurrisHAIII, MooreMJ, AndersenJ, et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol1997;15:2403–2413.
BurrisHAIII, MooreMJ, AndersenJ, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.10.1200/JCO.1997.15.6.24039196156)| false
OettleH, PostS, NeuhausP, et al.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA2007;297:267–277.
OettleH, PostS, NeuhausP, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267–277.1722797810.1001/jama.297.3.267)| false
OettleH, NeuhausP, HochhausA, et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA2013;310:1473–1481.
OettleH, NeuhausP, HochhausA, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473–1481.2410437210.1001/jama.2013.279201)| false
MackeyJR, ManiRS, SelnerM, et al.Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res1998;58:4349–4357.
MackeyJR, ManiRS, SelnerM, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349–4357.9766663)| false
FarrellJJ, ElsalehH, GarciaM, et al.Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology2009;136:187–195.
GreenhalfW, GhanehP, NeoptolemosJP, et al.Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst2014;106:djt347.
GreenhalfW, GhanehP, NeoptolemosJP, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014;106:djt347.2430145610.1093/jnci/djt347)| false
LiuZQ, HanYC, ZhangX, et al.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS One2014;9:e87103.
LiuZQ, HanYC, ZhangX, Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS One 2014;9:e87103.10.1371/journal.pone.008710324475233)| false
MarechalR, BachetJB, MackeyJR, et al.Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology2012;143:664–674 e661-666.
MarechalR, BachetJB, MackeyJR, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012;143:664–674 e661-666.10.1053/j.gastro.2012.06.00622705007)| false
SaifMW, LeeY, KimR.Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 2012;4:341–346.10.1177/175883401245375523118809)| false
ZhuY, QiM, LaoL, et al.Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomarkers2014;18:306–312.
ZhuY, QiM, LaoL, Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomarkers 2014;18:306–312.2462535310.1089/gtmb.2013.0419)| false
BirdNT, ElmasryM, JonesR, et al.Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br J Surg2017;104:328–336.
OrmannsS, HeinemannV, RaponiM, et al.Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer2014;50:1891–1899.
OrmannsS, HeinemannV, RaponiM, Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer 2014;50:1891–1899.10.1016/j.ejca.2014.04.023)| false
SinnM, RiessH, SinnBV, et al.Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer2015;51:1546–1554.
SinnM, RiessH, SinnBV, Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer 2015;51:1546–1554.10.1016/j.ejca.2015.05.005)| false
GrunewaldR, AbbruzzeseJL, TarassoffP, et al.Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol1991;27:258–262.
GrunewaldR, AbbruzzeseJL, TarassoffP, Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258–262.199898210.1007/BF00685109)| false
TemperoM, PlunkettW, Ruiz Van HaperenV, et al.Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol2003;21:3402–3408.
TemperoM, PlunkettW, Ruiz Van HaperenV, Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402–3408.1288583710.1200/JCO.2003.09.140)| false
PoplinE, FengY, BerlinJ, et al.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol2009;27:3778–3785.
PoplinE, FengY, BerlinJ, Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778–3785.1958153710.1200/JCO.2008.20.9007)| false
DemolsA, PeetersM, PolusM, et al.Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer2006;94:481–485.
DemolsA, PeetersM, PolusM, Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481–485.1643498810.1038/sj.bjc.6602966)| false
FineRL, FogelmanDR, SchreibmanSM, et al.The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol2008;61:167–175.
FineRL, FogelmanDR, SchreibmanSM, The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167–175.1744072710.1007/s00280-007-0473-0)| false
KoAH, EspinozaAM, JonesKA, et al.Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol2012;35:411–417.
KoAH, EspinozaAM, JonesKA, Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol 2012;35:411–417.2155209910.1097/COC.0b013e3182185888)| false
BerlinJD, CatalanoP, ThomasJP, et al.Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol2002;20:3270–3275.
BerlinJD, CatalanoP, ThomasJP, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270–3275.1214930110.1200/JCO.2002.11.149)| false
ColucciG, GiulianiF, GebbiaV, et al.Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer2002;94:902–910.
ColucciG, GiulianiF, GebbiaV, Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902–910.10.1002/cncr.10323)| false
ColucciG, LabiancaR, Di CostanzoF, et al.Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol2010;28:1645–1651.
ColucciG, LabiancaR, Di CostanzoF, Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645–1651.2019485410.1200/JCO.2009.25.4433)| false
CunninghamD, ChauI, StockenDD, et al.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol2009;27:5513–5518.
CunninghamD, ChauI, StockenDD, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513–5518.1985837910.1200/JCO.2009.24.2446)| false
HeinemannV, BoeckS, HinkeA, et al.Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer2008;8:82–82.
HeinemannV, BoeckS, HinkeA, Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82–82.10.1186/1471-2407-8-8218373843)| false
HeinemannV, QuietzschD, GieselerF, et al.Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol2006;24:3946–3952.
HeinemannV, QuietzschD, GieselerF, Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946–3952.1692104710.1200/JCO.2005.05.1490)| false
HeinemannV, LabiancaR, HinkeA, et al.Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol2007;18:1652–1659.
HeinemannV, LabiancaR, HinkeA, Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007;18:1652–1659.10.1093/annonc/mdm283)| false
HerrmannR, BodokyG, RuhstallerT, et al.Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol2007;25:2212–2217.
HerrmannR, BodokyG, RuhstallerT, Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212–2217.10.1200/JCO.2006.09.0886)| false
LouvetC, LabiancaR, HammelP, et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol2005;23:3509–3516.
LouvetC, LabiancaR, HammelP, Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509–3516.1590866110.1200/JCO.2005.06.023)| false
ReniM, CordioS, MilandriC, et al.Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol2005;6:369–376.
ReniM, CordioS, MilandriC, Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369–376.1592581410.1016/S1470-2045(05)70175-3)| false
Rocha LimaCM, GreenMR, RotcheR, et al.Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol2004;22:3776–3783.
Rocha LimaCM, GreenMR, RotcheR, Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776–3783.10.1200/JCO.2004.12.082)| false
CilibertoD, BottaC, CorrealeP, et al.Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer2013;49:593–603.
CilibertoD, BottaC, CorrealeP, Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013;49:593–603.2298951110.1016/j.ejca.2012.08.019)| false
KulkeMH, TemperoMA, NiedzwieckiD, et al.Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol2009;27:5506–5512.
KulkeMH, TemperoMA, NiedzwieckiD, Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009;27:5506–5512.1985839610.1200/JCO.2009.22.1309)| false
StathopoulosGP, SyrigosK, AravantinosG, et al.A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer2006;95:587–592.
StathopoulosGP, SyrigosK, AravantinosG, A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587–592.10.1038/sj.bjc.6603301)| false
GonçalvesA, GilabertM, FrançoisE, et al.BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol2012;23:2799–2805.
GonçalvesA, GilabertM, FrançoisE, BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23:2799–2805.10.1093/annonc/mds13522771827)| false
Von HoffDD, RamanathanRK, BoradMJ, et al.Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol2011;29:4548–4554.
Von HoffDD, RamanathanRK, BoradMJ, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548–4554.10.1200/JCO.2011.36.574221969517)| false
Von HoffDD, ErvinT, ArenaFP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.2413114010.1056/NEJMoa1304369)| false
ChioreanEG, Von HoffDD, ReniM, et al.CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol2016;27:654–660.
ChioreanEG, Von HoffDD, ReniM, CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016;27:654–660.10.1093/annonc/mdw006)| false
RamanathanRK, GoldsteinD, KornRL, et al.Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol2016;27:648–653.
RamanathanRK, GoldsteinD, KornRL, Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol 2016;27:648–653.2680215310.1093/annonc/mdw020)| false
GoldsteinD, Von HoffDD, MooreM, et al.Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer2016;52:85–91.
GoldsteinD, Von HoffDD, MooreM, Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer 2016;52:85–91.10.1016/j.ejca.2015.10.01726655559)| false
GoldsteinD, El-MaraghiRH, HammelP, et al.nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst2015;107:107.
GoldsteinD, El-MaraghiRH, HammelP, nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:107.10.1093/jnci/dju413)| false
TaberneroJ, ChioreanEG, InfanteJR, et al.Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist2015;20:143–150.
TaberneroJ, ChioreanEG, InfanteJR, Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015;20:143–150.10.1634/theoncologist.2014-0394)| false
BuccheriG, FerrignoD, TamburiniM.Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer1996;32A:1135–1141.
BuccheriG, FerrignoD, TamburiniM.Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135–1141.10.1016/0959-8049(95)00664-88758243)| false
MaC, BandukwalaS, BurmanD, Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010;46:3175–3183.10.1016/j.ejca.2010.06.12620674334)| false
GolanT, KanjiZS, EpelbaumR, et al.Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer2014;111:1132–1138.
GolanT, KanjiZS, EpelbaumR, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132–1138.10.1038/bjc.2014.41825072261)| false
MajdakEJ, DebniakJ, MilczekT, et al.Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer2005;104:1004–1012.
MajdakEJ, DebniakJ, MilczekT, Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:1004–1012.10.1002/cncr.2127616047333)| false
StefanssonOA, JonassonJG, JohannssonOT, et al.Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res2009;11:R47.
StefanssonOA, JonassonJG, JohannssonOT, Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.1958915910.1186/bcr2334)| false
OliverGR, SugarE, LaheruD, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Gastrointestinal Cancers Symposium 2010:180.
174.
LoweryMA, KelsenDP, StadlerZK, et al.An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist2011;16:1397–1402.
LoweryMA, KelsenDP, StadlerZK, An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397–1402.2193410510.1634/theoncologist.2011-0185)| false
MooreMJ, GoldsteinD, HammJ, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:1960–1966.
MooreMJ, GoldsteinD, HammJ, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.10.1200/JCO.2006.07.9525)| false
PhilipPA, BenedettiJ, CorlessCL, et al.Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol2010;28:3605–3610.
PhilipPA, BenedettiJ, CorlessCL, Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605–3610.10.1200/JCO.2009.25.755020606093)| false
KindlerHL, NiedzwieckiD, HollisD, et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol2010;28:3617–3622.
KindlerHL, NiedzwieckiD, HollisD, Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617–3622.10.1200/JCO.2010.28.1386)| false
KindlerHL, IokaT, RichelDJ, et al.Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol2011;12:256–262.
KindlerHL, IokaT, RichelDJ, Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12:256–262.2130695310.1016/S1470-2045(11)70004-3)| false
Van CutsemE, VervenneWL, BennounaJ, et al.Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol2009;27:2231–2237.
Van CutsemE, VervenneWL, BennounaJ, Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231–2237.1930750010.1200/JCO.2008.20.0238)| false
ArandaE, ManzanoJL, RiveraF, et al.Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol2012;23:1919–1925.
ArandaE, ManzanoJL, RiveraF, Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol 2012;23:1919–1925.10.1093/annonc/mdr56022156621)| false
StepanskiEJ, ReyesC, WalkerMS, et al.The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas2013;42:32–36.
StepanskiEJ, ReyesC, WalkerMS, The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas 2013;42:32–36.2269920310.1097/MPA.0b013e318254f19a)| false
LeeHS, ChungMJ, ParkJY, et al.A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore)2017;96:e5702.
LeeHS, ChungMJ, ParkJY, A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore) 2017;96:e5702.10.1097/MD.0000000000005702)| false
LiQ, YanH, LiuW, et al.Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One2014;9:e104346.
LiQ, YanH, LiuW, Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346.10.1371/journal.pone.010434625093849)| false
De Jesus-AcostaA, OliverGR, BlackfordA, et al.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol2012;69:415–424.
De Jesus-AcostaA, OliverGR, BlackfordA, A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012;69:415–424.10.1007/s00280-011-1704-y21800112)| false
PetrioliR, RovielloG, FiaschiAI, et al.Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemother Pharmacol2015;75:683–690.
PetrioliR, RovielloG, FiaschiAI, Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemother Pharmacol 2015;75:683–690.10.1007/s00280-015-2683-125618415)| false
TrouilloudI, Dupont-GossardAC, MalkaD, et al.Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer2014;50:3116–3124.
TrouilloudI, Dupont-GossardAC, MalkaD, Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer 2014;50:3116–3124.10.1016/j.ejca.2014.09.01525454414)| false
YanagimotoH, IshiiH, NakaiY, et al.Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J Hepatobiliary Pancreat Sci2014;21:761–766.
YanagimotoH, IshiiH, NakaiY, Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J Hepatobiliary Pancreat Sci 2014;21:761–766.10.1002/jhbp.13024925464)| false
LiY, SunJ, JiangZ, et al.Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother2015;27:227–234.
LiY, SunJ, JiangZ, Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother 2015;27:227–234.10.1179/1973947815Y.000000001325790948)| false
YamaueH, ShimizuA, HagiwaraY, et al.Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol2017;79:813–823.
YamaueH, ShimizuA, HagiwaraY, Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol 2017;79:813–823.10.1007/s00280-017-3250-828251282)| false
BoeckS, Vehling-KaiserU, WaldschmidtD, et al.Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs2010;21:94–100.
BoeckS, Vehling-KaiserU, WaldschmidtD, Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs 2010;21:94–100.10.1097/CAD.0b013e32833123ed19770635)| false
CartwrightTH, CohnA, VarkeyJA, et al.Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol2002;20:160–164.
CartwrightTH, CohnA, VarkeyJA, Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160–164.10.1200/JCO.2002.20.1.160)| false
PelzerU, SchwanerI, StielerJ, et al.Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer2011;47:1676–1681.
PelzerU, SchwanerI, StielerJ, Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676–1681.10.1016/j.ejca.2011.04.01121565490)| false
XiongHQ, VaradhacharyGR, BlaisJC, et al.Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer2008;113:2046–2052.
XiongHQ, VaradhacharyGR, BlaisJC, Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046–2052.1875653210.1002/cncr.23810)| false
KaufmanB, Shapira-FrommerR, SchmutzlerRK, et al.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol2015;33:244–250.
KaufmanB, Shapira-FrommerR, SchmutzlerRK, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244–250.10.1200/JCO.2014.56.2728)| false
RahmaOE, DuffyA, LiewehrDJ, et al.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol2013;24:1972–1979.
RahmaOE, DuffyA, LiewehrDJ, Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013;24:1972–1979.2367009310.1093/annonc/mdt166)| false
ChioreanEG, Von HoffDD, TaberneroJ, et al.Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer2016;115:e13.
ChioreanEG, Von HoffDD, TaberneroJ, Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer 2016;115:e13.10.1038/bjc.2016.306)| false
PelzerU, KubicaK, StielerJ, et al.A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol2008;26 (May 20 suppl):4508.
PelzerU, KubicaK, StielerJ, A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol 2008;26 (May 20 suppl):4508.10.1200/jco.2008.26.15_suppl.4508)| false
SaifMW.New developments in the treatment of pancreatic cancer. Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2008. JOP2008;9:391–397.
SaifMW.New developments in the treatment of pancreatic cancer. Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2008. JOP 2008;9:391–397.18648128)| false
OettleH, RiessH, StielerJM, et al.Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol2014;32:2423–2429.
OettleH, RiessH, StielerJM, Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423–2429.2498245610.1200/JCO.2013.53.6995)| false
GillS, KoYJ, CrippsC, et al.PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol2016;34:3914–3920.
GillS, KoYJ, CrippsC, PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016;34:3914–3920.10.1200/JCO.2016.68.5776)| false
UccelloM, MoschettaM, ArkenauHT.Second-line combination therapies in pancreatic cancer: where are we now?J Clin Oncol 2017;35:1370–1371.2811302210.1200/JCO.2016.71.0921)| false
ChungV, McDonoughS, PhilipPA, et al.Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol2017;3:516–522.
ChungV, McDonoughS, PhilipPA, Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol 2017;3:516–522.10.1001/jamaoncol.2016.538327978579)| false
Wang-GillamA, LiCP, BodokyG, et al.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet2016;387:545–557.
Wang-GillamA, LiCP, BodokyG, Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545–557.2661532810.1016/S0140-6736(15)00986-1)| false
Wang-GillamA, LiC-P, BodokyG, et al. Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy. ASCO Meeting Abstracts 2016;34:4126.
Wang-GillamA, LiC-P, BodokyG, Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy. ASCO Meeting Abstracts 2016;34:4126.10.1200/JCO.2016.34.15_suppl.4126)| false
YooC, HwangJY, KimJE, et al.A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer2009;101:1658–1663.
YooC, HwangJY, KimJE, A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658–1663.10.1038/sj.bjc.660537419826418)| false
NeuzilletC, HenticO, RousseauB, et al.FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol2012;18:4533–4541.
NeuzilletC, HenticO, RousseauB, FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012;18:4533–4541.10.3748/wjg.v18.i33.453322969226)| false
ZaniboniA, AitiniE, BarniS, et al.FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol2012;69:1641–1645.
ZaniboniA, AitiniE, BarniS, FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012;69:1641–1645.2257633810.1007/s00280-012-1875-1)| false
HeinemannV, Vehling-KaiserU, WaldschmidtD, et al.Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104). Gut2013;62:751–759.
HeinemannV, Vehling-KaiserU, WaldschmidtD, Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104). Gut 2013;62:751–759.2277355110.1136/gutjnl-2012-302759)| false
MarabelleA, LeDT, AsciertoPA, et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol2020;38:1–10.
MarabelleA, LeDT, AsciertoPA, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.3168255010.1200/JCO.19.02105)| false
DrilonA, LaetschTW, KummarS, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.2946615610.1056/NEJMoa1714448)| false
HongDS, DuBoisSG, KummarS, et al.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol2020;21:531–540.
HongDS, DuBoisSG, KummarS, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531–540.10.1016/S1470-2045(19)30856-332105622)| false
